Patients with advanced ovarian cancer have a higher likelihood of recurrence: over 80% recur after their first-line platinum treatment, according to Bhavana Pothuri, MD, gynecologic oncologist at the NYU Langone Medical Center Perlmutter Cancer Center. One of the reasons for this high rate of recurrence is treatments in the frontline not being effective right away, but that could now change with the addition of PARP inhibitors like niraparib (Zejula).
At the European Society of Medical Oncology 2019 Congress, OncLive®, a sister publication of Oncology Nursing News®, had the chance to interview Pothuri on the implications of the PRIMA study, presented at the conference. She highlighted the effectiveness of niraparib and where the future of PARP inhibitors could go from here.
We still need to think about all the data carefully, determine whether HRD testing is indicated in the upfront setting, whether patients who have BRCA-positive tumors or HRD-positive tumors should be prioritized to receive the PARP inhibitor in the frontline setting and perhaps thinking about different strategies in terms of utilizing maintenance in the biomarker-negative group.
You must log in to use this feature, please click here to login.